Interferon alpha and antisense K-ras RNA combination gene therapy
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 7, 2009
Grant Date -
Nov 24, 2005
app pub date -
Apr 26, 2005
filing date -
Apr 27, 2004
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Methods of suppressing growth of pancreatic tumors or cancer cells having a K-ras gene point mutation in a mammal, comprising: administering therapeutically effective amounts of adenoviral vector and antisense K-ras expressing vector to pancreatic cancer cells via intratumoral administration, wherein the adenoviral vector comprises a DNA sequence encoding a human IFN-alpha and operably linked to a promoter, and the pancreatic cancer cells to which the adenoviral vector is administered express the human IFN-alpha; and the antisense K-ras expressing vector comprises an antisense K-ras nucleotide sequence, wherein the antisense K-ras nucleotide sequence is operably linked to a promoter, and the pancreatic cancer cells to which the anti-sense K-ras expressing vector is administered express the antisense K-ras nucleotide sequence; whereby expression of the human IFN-alpha and the antisense K-ras nucleotide sequence suppress growth of pancreatic tumor or cancer cells in the mammal.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully